Keros Therapeutics (KROS) AI Stock Analysis

• Market Cap: $610.86M
• Dividend Yield: N/A
• Average Volume (3M): 699.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: 91657.69%
• EPS Growth: 97.21%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 3.62
• Shares Outstanding: 40,615,414
• 10 Day Avg. Volume: 515,638
• 30 Day Avg. Volume: 699,117
• PEG Ratio: 1.50
• Price to Book (P/B): 0.84
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.10
• Enterprise Value/Market Cap: -0.15
• Enterprise Value/Revenue: -0.42
• Enterprise Value/Gross Profit: -0.43
• Enterprise Value/Ebitda: 0.16
• 1Y Price Target: $24.17
• Price Target Upside: 71.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 46 Neutral
• Price Target: $14.00 ▼(-0.64%Downside)

Keros Therapeutics has a low overall stock score due to several factors. Financial performance is hindered by ongoing unprofitability and negative cash flows, which are typical of growth-stage biotech firms. Although technical analysis indicates some positive momentum, valuation remains challenged by the lack of profitability. Significant negative corporate events, including a major workforce reduction and strategic realignment, further weigh on the overall score.

Positive Factors

Financial Performance

A strong balance sheet with a total cash of $720.5M supports a financial runway into 2029, offering flexibility for future opportunities.

Product Development

Elritercept’s early progress, particularly in myelofibrosis, suggests Keros’ platform may be improved compared to Acceleron’s.

Strategic Direction

Management confirmed strong commitment to advancing the KER-065 program in DMD, indicating a focused strategic direction.

Negative Factors

Clinical Development

The safety profile of cibotercept does not support continued clinical development in PAH due to the risk of pericardial effusions.

Pipeline Confidence

Ahead of additional clarity on the company’s next steps and based on reduced confidence in the pipeline at this time, the analyst reiterates a Market Perform rating.

Workforce Reduction

Keros announced a corporate restructuring with a 45% headcount reduction, which is estimated to result in annualized cost savings of $17 million.

Keros Therapeutics Business Overview & Revenue Model

Company Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

How the Company Makes Money

Keros Therapeutics generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company earns money by advancing its pipeline of therapeutic candidates through clinical trials and eventually bringing successful treatments to market, where they can be sold to healthcare providers and patients. Key revenue streams include potential product sales, milestone payments, and royalties from licensing agreements with larger pharmaceutical companies. Additionally, strategic partnerships and collaborations with other biotech and pharmaceutical firms may provide Keros with funding support and shared resources, contributing to its revenue generation and financial growth.

Keros Therapeutics Financial Statement Overview

Summary

Keros Therapeutics shows significant revenue growth but remains unprofitable with negative margins, typical for early-stage biotech firms. The balance sheet is strong with a high equity ratio, but negative cash flow and reliance on external financing present long-term sustainability challenges.

Income Statement

Keros Therapeutics has experienced significant revenue growth, with an increase from $151K in 2023 to $3.55M in 2024. However, the company remains unprofitable with a negative EBIT margin of -5937% and a net profit margin of -5277% in 2024. This highlights ongoing challenges in managing operating expenses relative to revenues, typical of early-stage biotech firms.

Balance Sheet

The company's balance sheet shows a strong equity position with an equity ratio of 92.8% and a low debt-to-equity ratio of 0.03. However, the company consistently incurs losses, which could affect its ability to sustain this financial structure long-term without additional financing.

Cash Flow

Operating cash flow is negative, indicating the company is not generating sufficient cash from its operations. The free cash flow to net income ratio is positive but reflects heavy reliance on external financing, as seen in the substantial financing cash flow in 2024. This is a common situation for biotech companies investing heavily in R&D.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
214.71M	3.55M	151.00K	0.00	20.10M	0.00
	Gross Profit
214.07M	2.32M	-664.00K	-1.61M	19.20M	-605.00K
	EBIT
-10.31M	-210.83M	-169.94M	-114.79M	-56.37M	-46.66M
	EBITDA
-3.04M	-185.82M	-152.18M	-103.06M	-56.37M	-44.92M
	Net Income Common Stockholders
4.21M	-187.35M	-152.99M	-104.68M	-58.74M	-45.36M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.26M	559.93M	331.15M	279.05M	230.04M	265.88M
	Total Assets
0.00	615.89M	370.02M	306.78M	255.25M	269.44M
	Total Debt
0.00	18.86M	14.44M	13.27M	1.09M	899.00K
	Net Debt
23.26M	-541.07M	-316.70M	-265.78M	-228.95M	-264.98M
	Total Liabilities
0.00	44.33M	37.81M	29.36M	12.08M	7.72M
	Stockholders Equity
12.76M	571.55M	332.21M	277.42M	243.17M	261.72M
Cash Flow		Free Cash Flow
43.31M	-162.80M	-126.97M	-71.30M	-63.17M	-37.19M
	Operating Cash Flow
44.86M	-160.87M	-124.51M	-70.06M	-62.15M	-36.89M
	Investing Cash Flow
-1.55M	-1.93M	-2.46M	-1.24M	-1.02M	-294.00K
	Financing Cash Flow
235.02M	391.82M	178.96M	120.31M	28.55M	296.04M

Keros Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KROS, the sentiment is Negative. The current price of 14.09 is below the 20-day moving average (MA) of 14.29, above the 50-day MA of 13.41, and below the 200-day MA of 30.50, indicating a neutral trend. The MACD of 0.24 indicates Positive momentum. The RSI at 44.91 is Neutral, neither overbought nor oversold. The STOCH value of 36.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KROS.

Keros Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TBPH	55 Neutral	$562.51M	―	-31.46%	―	6.11%	-37.79%
MGTX	55 Neutral	$482.19M	―	-216.14%	―	203.23%	-80.71%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
KROS	46 Neutral	$610.86M	―	0.71%	―	91657.69%	97.21%
SAGE	45 Neutral	$428.95M	―	-63.53%	―	-47.94%	30.94%
TYRA	41 Neutral	$561.03M	―	-27.04%	―	―	6.72%
MNMD	40 Neutral	$588.56M	―	-37.07%	―	―	26.24%

Keros Therapeutics Corporate Events

Keros Therapeutics Concludes Strategic Alternatives Review

On June 4, 2025, Keros Therapeutics held its Annual Meeting of Stockholders, where stockholders voted on three proposals, including the election of directors, ratification of Deloitte & Touche LLP as the independent auditor, and approval of executive compensation. Subsequently, on June 9, 2025, Keros announced the conclusion of its strategic alternatives review, deciding to return $375 million in excess capital to stockholders. This decision reflects a thorough review of capital requirements and stockholder feedback, while the company continues to focus on developing KER-065 for neuromuscular diseases.

The most recent analyst rating on (KROS) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.

Keros Therapeutics CEO to Speak at Healthcare Conference

On June 6, 2025, Keros Therapeutics announced that its Chair and CEO, Jasbir Seehra, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025. This participation highlights Keros’ engagement with the healthcare investment community and may impact its visibility and industry positioning.

The most recent analyst rating on (KROS) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.

Keros Therapeutics Announces Major Workforce Reduction Plan

On May 28, 2025, Keros Therapeutics‘ Board of Directors approved a plan to reduce the company’s workforce by approximately 45%, aiming to align operations with strategic priorities and achieve cost savings. This reorganization, expected to be completed by the fourth quarter of 2025, follows the discontinuation of cibotercept development in pulmonary arterial hypertension due to safety concerns observed in the TROPOS trial. The company is evaluating strategic alternatives, including potential business transactions, to maximize shareholder value.

The most recent analyst rating on (KROS) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.

Keros Therapeutics CEO to Speak at Healthcare Conference

On May 12, 2025, Keros Therapeutics announced that its Chair and CEO, Jasbir S. Seehra, will participate in a fireside chat at the Bank of America 2025 Global Healthcare Conference on May 13, 2025. This participation highlights Keros’ engagement with the healthcare investment community and may enhance its visibility and influence within the industry.

The most recent analyst rating on (KROS) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.